Proactive Investors - Run By Investors For Investors

Summit Therapeutics to kick off gonorrhoeae trial next year

Identified using the company’s Discuva Platform, the new drug is designed to exploit the N. gonorrhoeae target
Summit Therapeutics to kick off gonorrhoeae trial next year
Cases of the sexually transmitted disease are on the rise

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) said it will kick off a Phase I clinical trial of a new antibiotic for gonorrhoea in the second half of next year.

It follows the nomination of SMT-571 as its lead candidate to tackle the sexually transmitted infection.

READ: Summit Therapeutics awarded additional US$12mln under contract with US BARDA

Identified using the company’s Discuva Platform, it is designed to exploit the N. gonorrhoeae target.

The study itself will be supported by the US$4.5mln it received from CARB-X, a US programme designed to accelerate the development of new antibiotics.

The need for new treatments for gonorrhoea was laid bare last week when the Centers for Disease Control and Prevention showed that cases of the STI had increased by 67% between 2013 and 2017.

Worrying also was the rise in drug-resistant strains of the infection.

“We believe our new science and new way of thinking together enable our goal to develop the right drug for the right pathogen and create opportunities for success,” said Dr David Roblin, Summit’s head of R&D of Summit.

“SMT-571 is being developed specifically for gonorrhoea, meaning that it is designed to have both a targeted spectrum of activity and be tailored to meet the needs of patients with gonorrhoea.”

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use